Drugs & Antimicrobials

A range of programmes with different industrial partners is in place at different points of the product development pathway, including bacterial (gram positive and gram negative) and fungal pathogens, malaria, TB and the NTDs, filariasis and onchocerciasis.

Our Research Centre for Drugs and Diagnostics works with industry, academia and other NGOs to discover, develop and deliver novel therapies and diagnostics against a range of pathogens. The Centre offers flexible models of collaboration from open access to commercial service provision.

The Centre for Antimicrobial Pharmacodynamics (CAP) provides state-of-the-art research facilities for pharmacokinetic-pharmacodynamic (PK-PD) studies for accelerating and de-risking drug development for tackling antimicrobial resistance.  We provide the preclinical and early phase clinical support to ensure new drugs are developed in a streamlined manner, as well as a complete, integrated drug development package.

 

 

Methicillin-Resistant Staphylococcus aureus (MRSA) - image courtesy NIAID https://www.flickr.com/photos/niaid/11854196633/in/album-72157629333420573/